Corcept Therapeutics reported a 13.8% year-over-year revenue increase to $207.6 million in Q3 2025, albeit with a significant drop in net income compared to the prior year. The company remains optimistic about future growth driven by expanding prescribing practices and upcoming product approvals.

• Adjusted 2025 revenue guidance is now between $800 million and $850 million.
• Net income decreased to $19.7 million from $47.2 million in Q3 2024.
• Korlym prescriptions surged 42.5%, outpacing supply due to capacity constraints; transitioning to a new pharmacy is underway.
• Confidence in relacorilant's commercial success, targeting $3 billion to $5 billion in annual revenue within 3-5 years.
• Two pivotal NDA applications for relacorilant are nearing their FDA deadlines, with significant clinical trial results anticipated in 2026.